Activities Report and Appendix 4C for December 2021 Quarter
Telix provides its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 December 2021.
FDA Approves Telix’s Prostate Cancer Imaging Product, Illuccix®
Telix and NUCLIBER Sign Distribution Agreement for Prostate Cancer Imaging in Spain
Telix announces agreement with NUCLIBER S.A. for the distribution of Telix’s prostate cancer investigational imaging product, Illuccix® in Spain.
Illuccix® Granted Use Authorisation for Prostate Cancer Imaging in Brazil
The Brazilian Health Regulatory Agency has granted an exceptional authorisation for Illuccix® (TLX591-CDx), Telix’s lead prostate cancer imaging product.
Australian TGA Approves Illuccix® for Prostate Cancer Imaging
Australian Therapeutic Goods Administration has approved Illuccix® for the diagnostic imaging of men with prostate cancer.
Activities Report and Appendix 4C for September 2021 Quarter
Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 September 2021.
Telix Establishes Commercial Hub in Geneva, Switzerland
Telix is pleased to announce that it has established a new commercial hub in Geneva through its subsidiary, Telix Pharmaceuticals (Switzerland) GmbH.
Telix and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging
Telix enters a commercial distribution agreement with Radius for Telix’s prostate cancer investigational imaging product Illuccix®
Telix In-Licences Novel Tumour Microenvironment PET Tracer
Telix announces an exclusive licence agreement for a novel PET radiotracer originating from the Université catholique de Louvain.
Telix to Collaborate with Kettering Health on Diagnostic PSMA Imaging & Targeting Theranostics
Telix announces collaboration with Kettering Health on PSMA-targeting theranostics